In 2024, Corealis Pharma unveiled an expansion of its facilities in Laval’s Biotech City, funded by over $10 million. This development increased the company’s premises from 33,000 to 63,000 square feet, allowing for the installation of new state-of-the-art laboratories. The expansion aims to enhance various aspects of Corealis’ operations, including formulation development and manufacturing of oral solid dosage forms, early-stage projects, analytical method development, integration of sophisticated equipment, and faster pace and scale of drug research and development. Additionally, the company plans to expand its clinical trial material manufacturing and packaging capabilities.
Corealis Pharma was founded in 2005 by Yves Roy, Patrick Gosselin, and Yves Mouget. The company quickly gained the trust of biotech companies globally and major pharmaceutical entities and has become one of the leading Contract Research and Development Organizations (CRO/CDMOs) in the world. In 2022, Corealis entered a partnership agreement with CDPQ and Archimed, a global investment firm focused on healthcare industries, to accelerate its expansion. The company saw a 20% increase in sales in 2023 thanks to its growing clientele in various regions worldwide.
The inauguration of the new facilities is part of a strategic plan to establish Corealis as a global leader in oral solid dosage form formulations while supporting Quebec’s reputation as a hub of excellence in biotechnology. The company’s growth and success are driven by its commitment to innovation and quality in the pharmaceutical industry.
